Increasing COPD awareness

European Respiratory Journal

Volumn 27, Issue 4, 2006, Pages 833-852

  Zielinski, J ^a   Bednarek, M ^a   Gorecka D ^a   Viegi, G ^b   Hurd, S S ^c   Fukuchi, Y ^d   Lai, C K W ^e   Ran, P X ^g   Ko, F W S ^e   Liu, S M ^g   Zheng, J P ^g   Zhong, N S ^g   Ip, M S M ^f   Vermeire, Paul A ^h  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c Global Initiative for Chronic Obstructive Lung Disease   (United States)

^d JUNTENDO UNIVERSITY   (Japan)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g GUANGZHOU MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; AWARENESS; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; FORCED EXPIRATORY VOLUME; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTPATIENT CARE; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SEX DIFFERENCE; SMOKING CESSATION; SMOKING HABIT; SPIROMETRY; CLINICAL TRIAL; HEALTH PROMOTION; MIDDLE AGED; MULTICENTER STUDY; POLAND; RISK FACTOR; SMOKING; VITAL CAPACITY;

ADULT; AGED; AWARENESS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH PROMOTION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; POLAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; SMOKING CESSATION; SPIROMETRY; VITAL CAPACITY;

EID: 33746915451     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00025905     Document Type: Article

References (103)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
2. GOLD Guidelines 2003. www.goldcopd.org/Guidelineitem. asp?11=2&12=1&intId=989. Last updated: September 2005. Last accessed: Febuary 5, 2005.
3. Mortality patterns - preliminary data, United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46: 941-944.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
5. Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257-266.
6. SobradilloPena V, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
7. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117: 339S-345S.
8. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-1689.
9. Morbidity & Mortality: chart book on cardiovascular, lung, and blood diseases. National Heart, Lung and Blood Institute. Bethesda, US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998.
10. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med 2002; 165: 704-707.
11. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
12. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
13. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
14. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
15. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG Jr. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146: 1345-1348.
16. Albers JMC, Schermer TRJ, van den Boom G, et al. Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: Results of the detection, intervention, and monitoring of COPD and asthma program. Chest 2004; 126: 1815-1824.
17. Van den Boom G, Rutten-van Mölken MPMH, Folgering HTM, van Weel C, van Schayck CP. The economic effects of screening for obstructive airway disease: An economic analysis of the DIMCA program. Prev Med 2000; 30: 302-308.
18. Zielinski J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001; 119: 731-736.
19. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
20. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16: Suppl., 5-40.
22. Connett JE, Bjornson-Benson WM, Daniels K. Recruitment of participants in the Lung Health Study: II Assessment of recruiting strategies. Lung Health Study Research Group. Control Clin Trials 1993; 14: 38S-51S.
23. van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002; 324: 1370-1375.
24. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125: 1394-1399.
25. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest 1999; 116: 416-423.
26. Schermer TR, Jacobs JE, Chavannes NH, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003; 58: 861-866.
27. Enright PL, Beck KC, Sherrill D. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 2004; 169: 235-238.
28. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
29. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117: 1146-1161.
30. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
31. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
32. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract 2004; 54: 201-206.
33. Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory epidemiology in Europe. Eur Respir Mon 2000; 5: 1-454.
34. Buist S, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 1-241.
35. European Respiratory Society. European Lung White Book. The first comprehensive survey on respiratory health in Europe. Huddersfield, European Respiratory Society, 2003.
36. Paoletti P, Carrozzi L, Viegi G, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking and level of pulmonary function. Am J Respir Crit Care Med 1995; 151: 1770-1777.
37. Sapigni T, Biavati P, Simoni M, et al. The Po River Delta Respiratory Epidemiological Survey: an analysis of factors related to level of total serum IgE. Eur Respir J 1998; 11: 278-283.
38. Viegi G, Paoletti P, Carrozzi L, et al. Prevalence rates of respiratory symptoms in Italian general population samples exposed to different levels of air pollution. Environ Health Perspect 1991; 94: 95-99.
39. Viegi G, Pedreschi M, Baldacci S, et al. Prevalence rates of respiratory symptoms and diseases in general population samples of North and Central Italy. Int J Tuberc Lung Dis 1999; 3: 1034-1042.
40. Viegi G, Matteelli G, Angino A, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004; 126: 1093-1101.
41. Guerra S, Sherrill DL, Baldacci S, et al. Rhinitis is an independent risk factor for developing cough apart from colds among adults. Allergy 2005; 60: 343-349.
42. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin Chest Med 2004; 25: 331-341.
43. Varkey AB. Chronic obstructive pulmonary disease in women: exploring gender differences. Curr Opin Pulm Med 2004; 10: 98-103.
44. Kauffmann F, Becklake MR. Sex and gender. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory epidemiology in Europe. Eur Respir Mon 2000; 5: 288-304.
45. Annesi-Maesano I, Agabiti N, Pistelli R, Couilliot MF, Forastiere F. Subpopulations at increased risk of adverse health outcomes from air pollution. Eur Respir J 2003; 21: Suppl. 40, 57s-63s.
46. Gold DR, Wang XW, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937.
47. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-827.
48. Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980; 122: 567-575.
49. Becklake MR. Gender differences in airway behaviour (physiology) over the human lifespan. In: Buist A, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 8-25.
50. Lebowitz MD, Knudson RJ, Burrows B. Tucson epidemiologic study of obstructive lung diseases: methodology and prevalence of disease. Am J Epidemiol 1975; 102: 137-152.
51. Barbee RA, Kaltenborn W, Lebowitz MD, Burrows B. Longitudinal changes in allergens skin test reactivity in a community population sample. J Allergy Clin Immunol 1987; 79: 16-24.
52. Cline MG, Burrows B. Distribution of allergy in a population sample residing in Tucson, Arizona. Thorax 1989; 44: 425-431.
53. Kauffmann F, Becklake MR. Maladies obstructives pulmonaires: un paradigme de la complexité des differences de sant ́entre hommes et femmes [Obstructive lung disease: a paradigma of the complexity of the differences in health between men and women]. In: Saurel-Cubizolles MJ, Blondell B, eds. La santé des femmes [The health of women]. Paris, Medecine et Sciences, 1996; pp. 209-233.
54. Manfreda J, Sears MR, Becklake MR, et al. Geographic and gender variability in the prevalence of bronchial responsiveness in Canada. Chest 2004; 125: 1657-1664.
55. Slama K. Active smoking. In: Annesi-Maesano I, Gulsvik A, Viegi G, eds. Respiratory epidemiology in Europe. Eur Respir Mon 2000; 5: 305-321.
56. Doll R. Risk from tobacco and potentials for health gain. Int J Tuberc Lung Dis 1999; 3: 90-99.
57. Prescott E, Osler M, Andersen PK, et al. Mortality in women and men and relation to smoking. Int J Epidemiol 1998; 27: 27-32.
58. Prescott E, Godtfredsen N, Vestbo J, Osler M. Social position and mortality from respiratory diseases in males and females. Eur Respir J 2003; 21: 821-826.
59. WHO Atlas maps global tobacco epidemic. Cent Eur J Public Health 2003; 11: 106.
60. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-852.
61. Ulrik CS. Smoking and mortality in women: "smoke like a man, die (at least) like a man". In: Buist S, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 103-117.
62. Watson L, Boezen HM, Postma DS. Differences between males and females in the natural history of asthma and COPD. In: Buist S, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 50-73.
63. Pierce JP, Fiore MC, Novontny TE, Hatziandreu EJ, Davis RM. Trends in cigarette smoking in the United States: projections to the year 2000. JAMA 1989; 261: 61-65.
64. Centers for Diseases Control and Prevention. Cigarette smoking among adults - United States, 1993. JAMA 1995; 273: 369-370.
65. Mannino DM, For DE, Giovino GA, Thun M. Lung cancer mortality rates in birth cohorts in the United States from 1960 to 1994. Lung Cancer 2001; 31: 91-99.
66. Pride NB, Soriano JB. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity, and smoking. Curr Opin Pulm Med 2002; 8: 95-101.
67. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 2003; 48: 1185-1191.
68. Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004; 8: 2-14.
69. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789-794.
70. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-1692.
71. Cerveri I, Accordini S, Corsico A, et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22: 413-417.
72. Blanc PD. The role of household exposures in lung disease among women. In: Buist S, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 118-130.
73. Wai Y, Tarlo SM. Occupational lung disease in women. In: Buist S, Mapp CE, eds. Respiratory diseases in women. Eur Respir Mon 2003; 8: 131-145.
74. Balmes J, Becklake M, Blanc P, et al. Environmental and Occupational Health Assembly, American Thoracic Society. American Thoracic Society Statement. Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003; 167: 787-797.
75. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
76. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481.
77. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998; 317: 465-468.
78. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute, NIH. http://www.nhlbi.nih.gov. Last accessed: February 5, 2005.
79. Fabbri LM, Hurd SS, for the GOLD Scientific Committee. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2.
80. US COPD Coalition. URL: http://www.uscopd.org. Last accessed: February 5, 2005.
81. Buist AS, Bailey W, Hurd SS. National COPD Conference Summary. J COPD 2004; 1: 293-302.
82. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD epidemiology study. Respirology 2004; 9: 458-465.
83. Japanese Respiratory Society Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease. Nihon Kokyuki Gakkai Zasshi 2004: 1-137.
84. Statistics Bureau, Director-General for Policy Planning, Ministry of Internal Affairs and Communications. www.stat.go.jp/english/index/ official/215.htm#1. Last accessed: February 6, 2006.
85. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
86. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-1778.
87. Shim YS. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency in Korea. Respirology 2001; 6: S9-S11.
88. 1-antitrypsin deficiency in Japan. Respirology 2001; 6: S35-S38.
89. Shin C, In KH, Shim JJ, et al. Prevalence and correlates of airway obstruction in a community-based sample of adults. Chest 2003; 123: 1924-1931.
90. World Health Organisation. World Health Report 2002. www.who.int/whr/ 2002. Last accessed: February 5, 2005.
91. Ministry of Public Health of China. Yearbook of China Healthcare 1998. Beijing, People's Health Publishing House, 1998; pp. 355-361.
92. Lai CKW, Ho SC, Lau J, et al. Respiratory symptoms in elderly Chinese living in Hong Kong. Eur Respir J 1995; 8: 2055-2061.
93. Regional COPD working group. COPD prevalence in 12-Asia Pacific countries and regions: Projections based on the COPD prevalence estimation model. Respirology 2003; 8: 192-198.
94. Buist S. Cookbook of the Burden of Obstructive Lung Disease. March 2004. www.goldcopd.com. Last accessed: February 5, 2005.
95. Zhong NS, Ran PX, Lau JC, et al. The burden of obstructive lung disease (BOLD) project in China: Prevalence of COPD in Guangzhou. Am J Respir Crit Care Med 2004; 169: A603.
96. Ferris BG. Recommended respiratory disease questionnaire for use with adults and children in epidemiology research. Am Rev Respir Dis 1978; 118: 7-53.
97. Cheng XS, Xu X, Zhang ZX. Results of community intervention trial for chronic obstructive pulmonary diseases and chronic cor pulmonale from 1992 to 1999. Chinese Journal of Tuberculosis and Respiratory Diseases 2001; 24: 579-583.
98. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
99. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonar disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
100. Sethi Sanjay. Bacterial exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenona? Proc Am Thorac Soc 2004; 1: 109-114.
101. Ko FW, Ng TK, Li TS, et al. Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong. Respirat Med 2005; 99: 454-460.
102. Chan CHS, Cohen M, Pang J. A prospective study of community acquired pneumonia in Hong Kong. Chest 1992; 101: 442-446.
103. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612.